Survival Data
One hundred seventy-five adult and pediatric transplant centers were included in the analysis of patients who received their first allogeneic transplant between January 1, 2020, and December 31, 2022, using unrelated or related donors, and who had reported follow-up. The one-year survival rate of patients transplanted at Northside was 82.6%. Data was reported in the Center for International Blood and Marrow Transplant Research Final 2024 Transplant Center Survival Report and from nmdp.org.
Northside was the ONLY adult BMT program in the U.S. that achieved survival outcomes that significantly exceeded their expected one-year survival rate for the last 16 consecutive reporting cycles (2009–2024). It is the largest allogenic program in Georgia and the ONLY transplant center in Georgia to exceed survival outcomes.
“The BMT Program at Northside is the largest allogeneic transplant program in Georgia,” said H. Kent Holland, M.D., medical director of the Northside BMT Program. “Our success is a direct reflection of the combined experience and expertise of the teams in our inpatient and outpatient BMT units, our stem-cell laboratory, and our blood donor center.”
Innovative treatments and research are major components of the NH-BMT. Northside offers chimeric antigen receptor (CAR) T-cell therapy, TIL therapy and other immunotherapy treatment options, including novel clinical research trials.
WHY WE ARE SO SUCCESSFUL
The BMT Program at Northside, one of the largest allogeneic transplant programs in Georgia, is in the top 2.5% of programs in the nation to achieve survival outcomes that are superior to their predicted rates. Our commitment to the highest quality standard has enabled our program to continue to outperform year after year.
We specialize in caring for high-risk and complicated patients in comparison with other centers that may select only favorable-risk patients.
Only attending BMT-focused physicians are involved in patient care versus residents, fellows, clinician-researchers, or physicians whose primary interest lies outside of blood and marrow transplant.
Our BMT physicians take first call on nights and weekends to provide immediate access.
Our highly organized and proactive Quality Improvement Program has served as a national model for other transplant centers.
Six consecutive tri-annual inspections by the Foundation for Accreditation of Cellular Therapy (FACT) found no detected deficiencies in the Clinical Program, which is an unprecedented accomplishment.
A high ratio of dedicated BMT pharmacists-to-patients prevents medication errors and ensures adherence to evidence-based algorithms.
We are the largest allogeneic BMT center in Georgia and one of the largest in the Southeast.
